DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF
DBV Technologies S.A.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 16, 2026
$8.97−0.08 (-0.88%)
Close on Oct 19, 2026
- Market cap
- $3.89B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Operating margin
-2609.2%−1200.6 pts over 5 years
Net margin
-2607.3%−1192.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +35.8% | +5.2% | -13.0% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -80.0% | -149.8% | |
| Return on assets | – | -58.7% | -98.2% | |
| Current ratio | – | 3.93 | 3.67 | |
| Capex to revenue | – | 24.7% | 9.4% | |
| Diluted shares | 24M | 54M | 140M |
Where the cash went
Fiscal 2021 to 2025, five years combined
DBV Technologies generated $469.22M from operations and spent $5.21M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$469.22M
Used
$5.21M
Capital expenditure$5.21M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2607.3%
×Asset turnover0.04×
×Equity multiplier1.53×
=Return on equity, FY2025-149.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -2607.3% | 0.04× | 1.53× | -149.8% |
| FY2024 | -2744.4% | 0.03× | 1.48× | -136.0% |
| FY2023 | 462.3% | 0.07× | 1.28× | 43.5% |
| FY2022 | 1987.5% | 0.02× | 1.34× | 65.6% |
| FY2021 | -1713.5% | 0.03× | 1.37× | -64.2% |
| FY2020 | -1415.0% | 0.04× | 1.36× | -80.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$146.95M
- Cash generatingOperating cash flow above zero-$121.18M
- Return on assets improvedROA up on the prior year-62.3% → -223.8%
- Earnings backed by cashOperating cash flow above net income-$121.18M vs -$146.95M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.43 → 3.67
- No dilutionShare count did not rise97M → 140M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.02 → 0.09